– Seasoned industry executives add significant operating experience to Pyxis’ Board of Directors – CAMBRIDGE, Mass., Sept. 7, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the appointments of Freda Lewis-Hall, M.D., Thomas Civik, Darren Cline, and Mark Chin to its Board of Directors. These strategic appointments strengthen the company’s operational, clinical, and […]
Pyxis Oncology Strengthens Board of Directors Read More »
Webinar on Tuesday, April 27th @ 1pm ET CAMBRIDGE, Mass., April 19, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced that it will host a key opinion leader (KOL) webinar on antibody-drug conjugates on Tuesday, April 27, 2021 at 1pm Eastern Time. Also featured will be a presentation by Pyxis Oncology Chief Executive
Pyxis Oncology Hosting Key Opinion Webinar on Antibody-Drug Conjugates Read More »
— New round enables Pyxis to advance differentiated antibody-drug conjugate (ADC) and immuno-oncology (I/O) programs to next value inflection point —— In addition to recently announced in-licensed ADC candidates and ADC toolkit from Pfizer, funding to support in-licensed ADC candidate from LegoChem Biosciences — CAMBRIDGE, Mass., March, 30, 2021 – Pyxis Oncology (“Pyxis” or the
— Pyxis expands developmental capabilities with license to two ADC programs and ADC technology platform toolkit developed by Pfizer — CAMBRIDGE, Mass., March 18, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for the development and commercialization of two antibody-drug
